A novel SARS-CoV-2 subunit vaccine engineered on an immune-activating platform technology

References

• Guglielmi G. The explosion of new coronavirus tests that could help to end the pandemic. Nature. 2020;583:1–6. doi:10.1038/d41586-020-02140-8.
   Google Scholar
• Habli Z, Saleh S, Zaraket H, Khraiche ML. COVID-19 in-vitro diagnostics: state-of-the-art and challenges for rapid, scalable, and high-accuracy screening. Front Bioeng Biotechnol. 2021;8.
   Google Scholar
• Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021;21(10):626–36. doi:10.1038/s41577-021-00592-1.
   PubMed Web of Science ®Google Scholar
• Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J, Appel C, Giattino C, Rodés-Guirao L. A global database of COVID-19 vaccinations. Nat Hum Behav. 2021;5(7):947–53. doi:10.1038/s41562-021-01122-8.
   PubMed Web of Science ®Google Scholar
• Asundi A, O’-Leary C, Bhadelia N. Global COVID-19 vaccine inequity: the scope, the impact, and the challenges. Cell Host Microbe. 2021;29(7):1036–39. doi:10.1016/j.chom.2021.06.007.
   PubMed Web of Science ®Google Scholar
• Peacocke EF, Heupink LF, Frønsdal K, Dahl EH, Chola L. Global access to COVID-19 vaccines: a scoping review of factors that may influence equitable access for low and middle-income countries. BMJ Open. 2021;11(9):49505. doi:10.1136/bmjopen-2021-049505.
   PubMed Web of Science ®Google Scholar
• Pan F, Zhao H, Nicholas S, Maitland E, Liu R, Hou Q. Parents’ decisions to vaccinate children against COVID-19: a scoping review. Vaccines. 2021;9(12):1476. doi:10.3390/vaccines9121476.
   Web of Science ®Google Scholar
• Ochieng C, Anand S, Mutwiri G, Szafron M, Alphonsus K. Factors associated with COVID-19 vaccine hesitancy among visible minority groups from a global context: a scoping review. Vaccines. 2021;9(12):1445. doi:10.3390/vaccines9121445.
   Web of Science ®Google Scholar
• Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, Watkinson P, Khunti K, Harnden A, Coupland CAC, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med. 2022;28:410–22.
   PubMed Web of Science ®Google Scholar
• Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y, Grinberg T, Auster O, Dagan N, Balicer RD, et al. Myocarditis after Covid-19 vaccination in a large health care organization. N Engl J Med. 2021;385:2132–39. doi:10.1056/NEJMoa2110737.
   PubMed Web of Science ®Google Scholar
• Ostrowski SR, Søgaard OS, Tolstrup M, Stærke NB, Lundgren J, Østergaard L, Hvas A-M. Inflammation and platelet activation after COVID-19 vaccines - possible mechanisms behind vaccine-induced immune thrombocytopenia and thrombosis. Front Immunol. 2021;12:779453. doi:10.3389/fimmu.2021.779453.
   PubMed Web of Science ®Google Scholar
• Perry RJ, Tamborska A, Singh B, Craven B, Marigold R, Arthur-Farraj P, Yeo JM, Zhang L, Hassan-Smith G, Jones M, et al. Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study. Lancet. 2021;398:1147–56. doi:10.1016/S0140-6736(21)01608-1.
   PubMed Web of Science ®Google Scholar
• Hsieh S-M, Liu M-C, Chen Y-H, Lee W-S, Hwang S-J, Cheng S-H, W-C K, Hwang K-P, Wang N-C, Lee Y-L, et al. Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan. Lancet Respir Med. 2021;9:1396–406. doi:10.1016/S2213-2600(21)00402-1.
   PubMed Web of Science ®Google Scholar
• Richmond P, Hatchuel L, Dong M, Ma B, Hu B, Smolenov I, Li P, Liang P, Han HH, Liang J, et al. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397:682–94. doi:10.1016/S0140-6736(21)00241-5.
   PubMed Web of Science ®Google Scholar
• Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, Plested JS, Zhu M, Cloney-Clark S, Zhou H, et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med. 2020;383:2320–32. doi:10.1056/NEJMoa2026920.
   PubMed Web of Science ®Google Scholar
• Dunkle LM, Kotloff KL, Gay CL, Áñez G, Adelglass JM, Barrat Hernández AQ, Harper WL, Duncanson DM, McArthur MA, Florescu DF, et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. N Engl J Med. 2021;386(6):531–43. doi:10.1056/NEJMoa2116185.
   PubMed Web of Science ®Google Scholar
• Martínez-Flores D, Zepeda-Cervantes J, Cruz-Reséndiz A, Aguirre-Sampieri S, Sampieri A, Vaca L. SARS-CoV-2 vaccines based on the spike glycoprotein and implications of new viral variants. Front Immunol. 2021;12. doi:10.3389/fimmu.2021.701501.
   PubMed Web of Science ®Google Scholar
• Pollet J, Chen W-H, Strych U. Recombinant protein vaccines, a proven approach against coronavirus pandemics. Adv Drug Deliv Rev. 2021;170:71–82. doi:10.1016/j.addr.2021.01.001.
   PubMed Web of Science ®Google Scholar
• Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, Chng MHY, Lin M, Tan N, Linster M, et al. SARS-CoV-2-Specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020;584:457–62. doi:10.1038/s41586-020-2550-z.
   PubMed Web of Science ®Google Scholar
• Klimstra WB, Nangle EM, Smith MS, Yurochko AD, Ryman KD. DC-SIGN and L-SIGN can act as attachment receptors for Alphaviruses and distinguish between mosquito cell-and mammalian cell-derived viruses. J Virol. 2003;77:12022–32. doi:10.1128/JVI.77.22.12022-12032.2003.
   PubMed Web of Science ®Google Scholar
• Granot T, Yamanashi Y, Meruelo D. Sindbis viral vectors transiently deliver tumor-associated antigens to lymph nodes and elicit diversified antitumor CD8+ T-cell immunity. Mol Ther. 2014;22:112–22. doi:10.1038/mt.2013.215.
   PubMed Web of Science ®Google Scholar
• Gardner JP, Frolov I, Perri S, Ji Y, MacKichan ML, zur Megede J, Chen M, Belli BA, Driver DA, Sherrill S, et al. Infection of human dendritic cells by a Sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein. J Virol. 2000;74:11849–57. doi:10.1128/JVI.74.24.11849-11857.2000.
   PubMed Web of Science ®Google Scholar
• Tseng J-C, Levin B, Hirano T, Yee H, Pampeno C, Meruelo D. In vivo antitumor activity of Sindbis viral vectors. J Natl Cancer Inst. 2002;94:1790–802. doi:10.1093/jnci/94.23.1790.
   PubMedGoogle Scholar
• Tseng JC, Levin B, Hurtado A, Yee H, De Castro IP, Jimenez M, Shamamian P, Jin R, Novick RP, Pellicer A, et al. Systemic tumor targeting and killing by Sindbis viral vectors. Nat Biotechnol. 2004;22:70–77. doi:10.1038/nbt917.
   PubMed Web of Science ®Google Scholar
• Yang L, Yang H, Rideout K, Cho T, Joo K Il, Ziegler L, Elliot A, Walls A, Yu D, Baltimore D, et al. Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat Biotechnol. 2008;26:326–34. doi:10.1038/nbt1390.
   PubMed Web of Science ®Google Scholar
• Hurtado A, Tseng J-C, Meruelo D. Gene therapy that safely targets and kills tumor cells throughout the body. Rejuvenation Res. 2006;9:36–44. doi:10.1089/rej.2006.9.36.
   PubMed Web of Science ®Google Scholar
• Tseng J, Hurtado A, Yee H, Levin B, Boivin C, Benet M, Blank SV, Pellicer A, Meruelo D. Using Sindbis viral vectors for specific detection and suppression of advanced ovarian cancer in animal models using Sindbis viral vectors for specific detection and suppression of advanced ovarian cancer in animal models. Cancer Res. 2004;64(18):6684–92. doi:10.1158/0008-5472.CAN-04-1924.
   PubMed Web of Science ®Google Scholar
• Morizono K, Ku A, Xie Y, Harui A, Kung SKP, Roth MD, Lee B, Chen ISY. Redirecting lentiviral vectors pseudotyped with Sindbis virus-derived envelope proteins to DC-SIGN by modification of N-linked glycans of envelope proteins. J Virol. 2010;84:6923–34. doi:10.1128/JVI.00435-10.
   PubMed Web of Science ®Google Scholar
• Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA, Davenport MP. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27:1205–11. doi:10.1038/s41591-021-01377-8.
   PubMed Web of Science ®Google Scholar
• Bertoletti A, Le Bert N, Qui M, Tan AT. SARS-CoV-2-Specific T cells in infection and vaccination. Cell Mol Immunol. 2021;18:2307–12. doi:10.1038/s41423-021-00743-3.
   PubMed Web of Science ®Google Scholar
• Sprent J, King C. COVID-19 vaccine side effects: the positives about feeling bad. Sci Immunol. 2021;6. doi:10.1126/sciimmunol.abj9256.
   PubMed Web of Science ®Google Scholar
• Cagigi A, Loré K. Immune responses induced by mRNA vaccination in mice, monkeys and humans. Vaccines. 2021;9:61. doi:10.3390/vaccines9010061.
   PubMed Web of Science ®Google Scholar
• Richards KA, Moritzky S, Shannon I, Fitzgerald T, Yang H, Branche A, Topham DJ, Treanor JJ, Nayak J, Sant AJ. Recombinant HA-based vaccine outperforms split and subunit vaccines in elicitation of influenza-specific CD4 T cells and CD4 T cell-dependent antibody responses in humans. NPJ Vaccines. 2020;5:77. doi:10.1038/s41541-020-00227-x.
   PubMed Web of Science ®Google Scholar
• Cox MMJ. Recombinant protein vaccines produced in insect cells. Vaccine. 2012;30:1759–66. doi:10.1016/j.vaccine.2012.01.016.
   PubMed Web of Science ®Google Scholar